The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects

被引:201
作者
Bode, AM [1 ]
Dong, ZG [1 ]
机构
[1] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA
关键词
mitogen-activated protein kinase; nuclear factor kappa B; activator protein-1; JB6 epidermal cells; apoptosis; tumor; cancer;
D O I
10.1016/S1040-8428(01)00215-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Arsenic is a well-documented carcinogen that also appears to be a valuable therapeutic tool in cancer treatment. This creates a paradox for which no unified hypothesis has been reached regarding the molecular mechanisms that determine whether arsenic will act as a carcinogen or as an effectual chemotherapeutic agent. Much of our knowledge with respect to the actions of arsenic has been drawn from epidemiological or clinical studies. The actions of arsenic are likely to be related to cell type, arsenic species, and length and dose of exposure. Arsenic unquestionably induces apoptosis and may specifically target certain tumor cells. Research data strongly suggest that arsenic influences distinct signaling pathways involved in mediating proliferation or apoptosis, including mitogen-activated protein kinases, p53, activator protein-1 or nuclear factor kappa B. The primary purpose of this review is to examine recent findings, from this laboratory and others, that focus on the molecular mechanisms of arsenic's actions in cell transformation and as a therapeutic agent. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:5 / 24
页数:20
相关论文
共 197 条
  • [81] Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase
    Hossain, K
    Akhand, AA
    Kato, M
    Du, J
    Takeda, K
    Wu, JH
    Takeuchi, K
    Liu, W
    Suzuki, H
    Nakashima, I
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (08) : 4290 - 4297
  • [82] Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan
    Hsu, CH
    Yang, SA
    Wang, JY
    Yu, HS
    Lin, SR
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (07) : 1080 - 1086
  • [83] Huang CS, 1998, CANCER RES, V58, P4102
  • [84] Huang CS, 1999, CANCER RES, V59, P3053
  • [85] Requirement of Erk, but not JNK, for arsenite-induced cell transformation
    Huang, CS
    Ma, WY
    Li, JX
    Goranson, A
    Dong, ZG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (21) : 14595 - 14601
  • [86] Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation
    Huang, CS
    Schmid, PC
    Ma, WY
    Schmid, HHO
    Dong, ZG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (07) : 4187 - 4194
  • [87] Induction of mitosis-mediated apoptosis by sodium arsenite in HeLaS3 cells
    Huang, SC
    Huang, CYF
    Lee, TC
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 60 (06) : 771 - 780
  • [88] Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy
    Huang, SY
    Yang, CH
    Chen, YC
    [J]. LEUKEMIA & LYMPHOMA, 2000, 38 (3-4) : 283 - +
  • [89] Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
    Huang, XJ
    Wiernik, PH
    Klein, RS
    Gallagher, RE
    [J]. MEDICAL ONCOLOGY, 1999, 16 (01) : 58 - 64
  • [90] Is the human carcinogen arsenic carcinogenic to laboratory animals?
    Huff, J
    Chan, P
    Nyska, A
    [J]. TOXICOLOGICAL SCIENCES, 2000, 55 (01) : 17 - 23